Primary Sclerosing Cholangitis Treatment Market by Product and Geography - Forecast and Analysis 2020-2024
| Published: Dec 2020 | Pages: 120 | SKU: IRTNTR45680 |
The primary sclerosing cholangitis treatment market size has the potential to grow by USD 37.50 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period.
This report provides a detailed analysis of the market by product (UDCA and other therapeutics) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Lannett Co. Inc., Mylan NV, Strides Pharma Science Ltd., and Teva Pharmaceutical Industries Ltd.
Market Overview
Browse TOC and LoE with selected illustrations and example pages of Primary Sclerosing Cholangitis Treatment Market
Market Competitive Analysis
The primary sclerosing cholangitis treatment market is fragmented. AbbVie Inc., Amneal Pharmaceuticals Inc., and Apotex Inc. are some of the major market participants. Factors such as a rise in the number of liver transplants and UDCA treatment, increasing incidence of diseases associated with primary sclerosing cholangitis, and growth in the availability of treatment will offer immense growth opportunities. However, poor understanding of primary sclerosing cholangitis pathogenesis, late detection of primary sclerosing cholangitis, and overlap syndromes creating problems during diagnosis may impede market growth. To make the most of the opportunities, vendors should focus on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market position, this primary sclerosing cholangitis treatment market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this primary sclerosing cholangitis treatment market analysis report provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading companies, including:
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Dr. Reddys Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson
- Lannett Co. Inc.
- Mylan NV
- Strides Pharma Science Ltd.
- Teva Pharmaceutical Industries Ltd.
Primary Sclerosing Cholangitis Treatment Market: Segmentation by Geography
For more insights on the market share of various regions Request for a FREE sample now!
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. North America will offer several growth opportunities to market vendors during the forecast period.
47% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for primary sclerosing cholangitis treatment in North America. This report provides an accurate prediction of the contribution of all segments to the growth of the primary sclerosing cholangitis treatment market size.
Primary Sclerosing Cholangitis Treatment Market: Key Highlights of the Report for 2020-2024
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will drive primary sclerosing cholangitis treatment market growth during the next five years
- Precise estimation of the primary sclerosing cholangitis treatment market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the primary sclerosing cholangitis treatment industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of primary sclerosing cholangitis treatment market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
|
Primary Sclerosing Cholangitis Treatment Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2019 |
|
Forecast period |
2020-2024 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4% |
|
Market growth 2020-2024 |
$ 37.50 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
3.43 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 47% |
|
Key consumer countries |
US, Germany, UK, Japan, and Canada |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Lannett Co. Inc., Mylan NV, Strides Pharma Science Ltd., and Teva Pharmaceutical Industries Ltd. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- UDCA - Market size and forecast 2019-2024
- Other therapeutics - Market size and forecast 2019-2024
- Market opportunity by Product
Customer landscape
- Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
- Competitive scenario
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Dr. Reddys Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson
- Lannett Co. Inc.
- Mylan NV
- Strides Pharma Science Ltd.
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
primary sclerosing cholangitis treatment market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis